SCHEMBL14546644

SCHEMBL14546644

COC1[C@@H](CO)O[C@@H](n2cnc(C(N)=O)n2)[C@H]1O

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.74
▸ SMN1; SMN2 Q16637 3/20 0.74
▸ ADORA1 P30542 3/20 0.74
▸ ALDH1A1 P00352 3/20 0.74
▸ TSHR P16473 2/20 0.74
▸ THPO P40225 2/20 0.74
▸ PMP22 Q01453 2/20 0.74
▸ GLA P06280 1/20 0.74
▸ EIF4E P06730 1/20 0.74
▸ CYP3A4 P08684 1/20 0.74
▸ TOP1 P11387 1/20 0.74
▸ PNP P00491 3/20 0.57
▸ TMEM97 Q5BJF2 2/20 0.44
▸ HTR2C P28335 1/20 0.44
▸ HTR2B P41595 1/20 0.44
▸ SLC6A3 Q01959 1/20 0.44
▸ KDM4E B2RXH2 2/20 0.42
▸ HTT P42858 2/20 0.42
▸ BLM P54132 2/20 0.42
▸ TP53 P04637 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15031296 0.91 LMNA (0.74) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
SCHEMBL13524851 0.89 LMNA (0.58) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
SCHEMBL13524854 0.89 LMNA (0.58) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
Ribavirin SCHEMBL6027558 0.85 LMNA (1.00) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
Ribavirin SCHEMBL5476700 0.85 LMNA (1.00) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
Ribavirin SCHEMBL3727 0.85 LMNA (1.00) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
Ribavirin SCHEMBL2619251 0.85 LMNA (1.00) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
Ribavirin SCHEMBL20806078 0.85 LMNA (1.00) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
Ribavirin SCHEMBL21311208 0.85 LMNA (1.00) LMNASMN1; SMN2ADORA1ALDH1A1TSHR
Ribavirin SCHEMBL12658449 0.85 LMNA (1.00) LMNASMN1; SMN2ADORA1ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070087960-A1 Treating hepatitis C virus infections; antivirals have low toxicity to the host; inhibit Flaviviridae polymerase IDENIX PHARMACEUTICALS LLC 2007-04-19 — — US disclosed
US-20070060541-A1 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections IDENIX PHARMACEUTICALS, INC. 2007-03-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060541-A1 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections PNP, NSUN2, HAVCR2 LMNA 981/4885SMN1; SMN2 626/4885ADORA1 419/4885
US-20070087960-A1 Treating hepatitis C virus infections; antivirals have low toxicity to the host; inhibit Flaviviridae polymerase HAVCR2, UGT1A3, UGT1A1 LMNA 2662/4885SMN1; SMN2 2478/4885ADORA1 635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback